May 2022

Climate concerns have been an ongoing topic that we will also address in May's issue. In other news, we will explore how new data on vaginal microbe compositions and their functions could impact the way we treat related conditions. We’ll also take a look at how e-commerce can actually cut insulin costs for patients, and how this would affect payers and manufacturers.


We’ll also look at how pharma can keep the “feel-good” sentiments it garnered pre-pandemic, alive. Whilst the success stories of Pfizer and Moderna increased people’s trust in pharma during the pandemic, some hiccups in Covid-19 vaccines like with J&J and AstraZeneca's jabs, caused the positive outlook to fall, it has been reported.

EDITORIAL

Editor | Jennifer C Smith-Parker

Writers | Darcy Jimenez, Manasi Vaidya, William Newton​​​​​​​, Adam Zamecnik.
Magazine Designer | Maria Gimenez

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Filipe Costa, Martina Labaiova, Dimeji Akinkuolie, Will Ingham
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Two years of Covid-19Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Controlant Company InsightGo to article: ControlantGo to article: Contract Pharmaceuticals Limited CanadaGo to article: CommentGo to article: Ukraine: Russian invasion could cause spike in Covid-19 cases Go to article: First vaccines, now drugs: FDA’s second wave of emergency Covid-19 approvalsGo to article: International Women’s Day spotlight: endometriosisGo to article: Remote audits – stopgap measure or the new normal?Go to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: BaxterGo to article: In DepthGo to article: Two years of Covid-19: lessons the pandemic taught about delivering essential vaccinesGo to article: A perfect storm: Covid-19 viral vector manufacturing adds further burden to CAR-Go to article: Russia sanctions: what next for Sputnik Covid-19 vaccine production around the wGo to article: Profit for patients: can NFTs allow people to monetise their health data?Go to article: Navigating distribution challenges for rare disease drugsGo to article: NiproGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DataGo to article: North America is seeing a hiring boom in pharma digital media rolesGo to article: Filings buzz: 23% increase in industrial automation mentions in Q3 of 2021Go to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue